Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding-Reference-Cited by-同舟云学术

Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding

Published:2014-11-29 Issue:1 Volume:15 Page:
ISSN:2050-6511
Container-title:BMC Pharmacology and Toxicology
language:en
Short-container-title:BMC Pharmacol Toxicol

Author:

Laurieri Nicola,Kawamura Akane,Westwood Isaac M,Varney Amy,Morris Elizabeth,Russell Angela J,Stanley Lesley A,Sim Edith

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1186/2050-6511-15-68.pdf

Reference61 articles.

1. Weber WW, Hein DW: N- acetylation pharmacogenetics. Pharmacol Rev. 1985, 37: 25-79.

2. Sim E, Abuhammad A, Ryan A: Arylamine N- acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol. 2014, 171: 2705-2725. 10.1111/bph.12598.

3. Blum M, Grant DM, McBride W, Heim M, Meyer UA: Human arylamine N- acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990, 9: 193-203. 10.1089/dna.1990.9.193.

4. Hickman D, Risch A, Buckle V, Spurr NK, Jeremiah SJ, McCarthy A, Sim E: Chromosomal localization of human genes for arylamine N- acetyltransferase. Biochem J. 1994, 297 (Pt 3): 441-445.

5. Hein DW: N- acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol. 2009, 5: 353-366. 10.1517/17425250902877698.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small Molecule Inhibitors of Arylamine N-Acetyltransferase 1 Attenuate Cellular Respiration;ACS Pharmacology & Translational Science;2024-07-17

2. Arylamine N-Acetyltransferases;Reference Module in Biomedical Sciences;2024

3. Novel targets in drug discovery;Pharmacognosy;2024

4. The arylamine N-acetyltransferases as therapeutic targets in metabolic diseases associated with mitochondrial dysfunction.;Pharmacological Reviews;2023-12-07

5. Non-coding and intergenic genetic variants of human arylamine N-acetyltransferase 2 (NAT2) gene are associated with differential plasma lipid and cholesterol levels and cardiometabolic disorders;Frontiers in Pharmacology;2023-04-03